Journal of gastrointestinal and liver diseases : JGLD最新文献

{"title":"Duodenal Hemangioma: A Rare Cause of Iron Deficiency Anemia.","authors":"Sidney C Davis, Michael Makar, Mark Joseph Mentrikoski, Sara West","doi":"10.15403/jgld-5760","DOIUrl":"https://doi.org/10.15403/jgld-5760","url":null,"abstract":"","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"33 4","pages":"451"},"PeriodicalIF":0.0,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142904628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Idiosyncratic acute liver failure induced by Tirzepatide.","authors":"Isis Terrington, Kristian Thomas, Helen Stone, Jonathan Coad, Salim Khakoo","doi":"10.15403/jgld-5967","DOIUrl":"https://doi.org/10.15403/jgld-5967","url":null,"abstract":"","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"33 4","pages":"574-575"},"PeriodicalIF":0.0,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142904430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A History of the Discovery of Helicobacter Pylori, with Special Reference to Giulio Bizzozero.","authors":"Raul Jesus Lazarate Cuba, Eamonn Martin Quigley","doi":"10.15403/jgld-5942","DOIUrl":"https://doi.org/10.15403/jgld-5942","url":null,"abstract":"<p><p>Helicobacter pylori is a microorganism that is highly prevalent in mankind and closely linked to several gastroduodenal disorders. Though Helicobacter pylori was introduced to the scientific community in 1983 by Robin Warren and Barry Marshall, a closely related Helicobacter species had been described one hundred years earlier by the Italian pathologist Giulio Bizzozero in the canine stomach. In this review we analyze the different steps involved in the discovery of Helicobacter and provide a biography of the pioneer Giulio Bizzozero.</p>","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"33 4","pages":"535-541"},"PeriodicalIF":0.0,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142904639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diverticulitis with Colovenous Fistula and Pylephlebitis: Imaging Findings of a Rare Case.","authors":"Mustafa Koyun, Bunyamin Ece","doi":"10.15403/jgld-5778","DOIUrl":"https://doi.org/10.15403/jgld-5778","url":null,"abstract":"","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"33 4","pages":"452"},"PeriodicalIF":0.0,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142904625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of 8-week Treatment with Glecaprevir/Pibrentasvir in Treatment-naïve or -experienced HCV Patients: Results from an Observational Retrospective Study in Real-life Settings (ODYSSEY).","authors":"Anca Trifan, Carol Stanciu, Adrian Streinu-Cercel, Augustina Culinescu, Liliana Baroiu, Eugen Dumitru, Cristina Pojoga, Ciprian Brisc, Mihaela Mihaela Brisc, Dan Ionut Gheonea, Dan Nicolae Florescu, Corina Silvia Pop, Laura Sorina Diaconu, Laura Munteanu, Laura Iliescu, Mircea Diculescu, Carmen Ester, Liliana Gheorghe","doi":"10.15403/jgld-5745","DOIUrl":"10.15403/jgld-5745","url":null,"abstract":"<p><strong>Background and aims: </strong>Pan-genotypic ribavirin-free oral direct-acting antivirals, including the glecaprevir/pibrentasvir combination, are recommended for the treatment of most patients with chronic hepatitis C virus (HCV) infection. In Romania, the HCV-infected patient population receiving glecaprevir/pibrentasvir is not well characterized and data on treatment effectiveness is lacking. The ODYSSEY study aimed to provide insights into the characteristics and treatment outcomes of HCV-infected Romanian patients receiving 8-week therapy with glecaprevir/pibrentasvir.</p><p><strong>Methods: </strong>This observational, retrospective medical chart review study was based on a Patient Support Program for HCV-infected patients (HCV-PSP) attending clinical practices in Romania and initiating glecaprevir/pibrentasvir between 01 February 2022 and 11 July 2023. Patients ≥18 years of age with compensated liver disease F0-F4 fibrosis grade treatment-naïve or F0-F3 fibrosis grade treatment-experienced on previous interferon-based regimens from the HCV-PSP were included in the ODYSSEY study. Patients received glecaprevir/pibrentasvir for at least 8 weeks. Sustained virological response (SVR) was assessed at 12 weeks after the 8-week treatment (SVR12). Analyses were conducted on the core population (CP) and the CP with sufficient follow-up data (CPSFU).</p><p><strong>Results: </strong>The CP and CPSFU included 2,240 and 2,165 patients, respectively. In both populations, most patients were female (≥67.57%), aged >50 years (≥73.62%), and treatment-naïve (≥96.47%). F4 fibrosis was reported in 19% of patients. Hypertension was the most common relevant comorbidity, reported for 21% of patients; comorbidity rates increased with age. Overall SVR12 rates were 96.1% [95% confidence interval (CI): 95.2-96.8%) and 99.3% (95%CI: 98.9-99.6) in the CP and CPSFU, respectively. When stratified by gender, age category, comorbidities or fibrosis grade, SVR12 rates were >92% in the CP [except for the subgroups of patients with chronic kidney disease (87.5%) and depressive-/anxiety disorders (86.2%)] and ≥97.0% in the CPSFU. SVR12 rates were higher in female patients. In an exploratory analysis, in the CPSFU, the presence of diabetes mellitus [odds ratio (OR)=3.840; 95%CI: 1.093-13.495] and cardiovascular diseases (OR=7.904; 95%CI: 1.719-36.346) were associated with an increased probability to detect HCV RNA at 12 weeks post-treatment.</p><p><strong>Conclusions: </strong>The 8-week treatment with glecaprevir/pibrentasvir resulted in high SVR12 rates for multiple HCV-infected patient profiles encountered in real-life settings in Romania.</p>","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"33 4","pages":"503-509"},"PeriodicalIF":0.0,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142904654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastric perineurioma: a rare entity with different clinical presentations. A case report.","authors":"Miriam Fiocca, Francesca Rosini, Giulio Cariani, Vincenzo Stanghellini, Giovanni Barbara, Giovanni Marasco","doi":"10.15403/jgld-5829","DOIUrl":"https://doi.org/10.15403/jgld-5829","url":null,"abstract":"","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"33 4","pages":"572-573"},"PeriodicalIF":0.0,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142904428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Sex Hormones and Sex Hormone-binding Globulin in Functional Gatrointestinal Disorders: A Bidirectional Two-sample Mendelian Randomization Study.","authors":"Zhengyang Fan, Changming Shao, Zhifu Kou, Feng Xie, Hongyu Wang, Shuai Zheng, Bo Wen, Zheng Chen, Binfang Zeng","doi":"10.15403/jgld-5642","DOIUrl":"https://doi.org/10.15403/jgld-5642","url":null,"abstract":"<p><strong>Background and aims: </strong>Sex hormones and sex hormone-binding globulin (SHBG) have been confirmed to involve in the pathophysiology of functional gastrointestinal disorders (FGIDs), including irritable bowel syndrome (IBS) and functional dyspepsia (FD). However, causal associations have not yet been investigated. Utilizing data from Genome-wide association studies, we conducted bidirectional two-sample mendelian randomization (MR) analyses to assess the causal relationships between sex hormones, SHBG and FGIDs.</p><p><strong>Methods: </strong>Data for sex hormones including testosterone and estradiol, and SHBG were collected from the UK Biobank and FinnGen study. Relevant single nucleotide polymorphisms (SNPs) were selected as instrumental variables (IVs). Inverse variance weighted (IVW) analysis were performed to assess the causal relationships., supplemented with MR-Egger, weighted median, and weighted mode approaches. Additionally, we used Cochran's Q test to evaluate the heterogeneity of genetic variants and implemented leave-one-out analysis to assess the impact of individual SNPs on the causal estimates. Several sensitivity analyses were conducted to assess the robustness of the results.</p><p><strong>Results: </strong>Significant negative causal relationship was found between genetically predicted testosterone and the risk of IBS (OR=0.90, 95%CI: 0.83-0.97; p=0.007). SHBG demonstrated an inverse correlation with the risk of IBS (OR=0.82, 95%CI: 0.68-0.98; p=0.035) and FD (OR=0.83, 95%CI: 0.69-0.99; p=0.048). However, no statistically significant association was found between testosterone and FD, while estradiol also showed no causal association with FGIDs.</p><p><strong>Conclusions: </strong>Our study revealed a negative causal relationship between testosterone and IBS risk, and SHBG appears to be inversely associated with FD. This provided new ideas for the prevention and control of IBS, and future research is warranted to elucidate the underlying mechanisms driving these associations and their potential clinical implications.</p>","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"33 4","pages":"474-481"},"PeriodicalIF":0.0,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142904634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Role of Brain Fog, Fatigue, and Psychological Distress on Quality of Life in Individuals Living with Inflammatory Bowel Disease: A Cross-sectional Study.","authors":"Simon R Knowles, Matthew Dickinson","doi":"10.15403/jgld-5759","DOIUrl":"https://doi.org/10.15403/jgld-5759","url":null,"abstract":"<p><strong>Background and aims: </strong>Despite reports of brain fog in patients with inflammatory bowel disease (IBD), empirical research into this phenomenon has been lacking. This study aimed to validate a brain fog scale and explore the relationships between IBD symptom activity, brain fog, fatigue, psychological distress, and quality of life (QoL).</p><p><strong>Method: </strong>A cross-sectional online study.</p><p><strong>Results: </strong>Of the 170 adults with IBD (mean age 38.75 years, 85.9% female, 62.35% Crohn's disease), 94.10% percent reported experiencing brain fog, with the majority (53.75%) experiencing brain fog at least 2 times a week, with each episode lasting around 2 hours. A confirmatory factor analysis supported the first hypothesis, demonstrating validity and stability of the brain fog scale in an IBD sample. Correlation analyses supported the second hypothesis, revealing positive relationships between IBD symptom activity and brain fog, fatigue and psychological distress, and a negative relationship between IBD symptom activity and QoL. A structural equation model with excellent fit (CMIN/df=1.84, p=0.137, TLI=0.98, CFI=0.99, SRMR=0.03, and RMSEA=0.07), provided support for the third hypothesis in that the relationship between IBD symptom activity and QoL was fully mediated by brain fog, fatigue, and psychological distress.</p><p><strong>Conclusions: </strong>This is the first study to explore the lived experience of brain fog and to validate the brain fog scale in an IBD sample. The study provides evidence that like fatigue, brain fog is not only common in IBD cohorts but is also frequent and adversely impacts psychological distress and QoL.</p>","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"33 4","pages":"488-495"},"PeriodicalIF":0.0,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142904425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Rectal Submucosal Squamous Cell Carcinoma Metastasis Case Mimicking a 4th Layer Lesion in EUS.","authors":"Hasan Eruzun, Hatice Ölger Uzuner, Kasım Demir","doi":"10.15403/jgld-5837","DOIUrl":"https://doi.org/10.15403/jgld-5837","url":null,"abstract":"","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"33 4","pages":"454"},"PeriodicalIF":0.0,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142904644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Biopsy-proven Nonalcoholic Fatty Liver Disease with Obesity and Apolipoproteins.","authors":"Ömer Kurt, Kadir Ozturk, Hakan Demirci, Ahmet Tas, Yıldırım Karslioglu, Turker Turker, Cafer Ozdemir, Taner Ozgurtas, Ahmet Uygun","doi":"10.15403/jgld-5550","DOIUrl":"https://doi.org/10.15403/jgld-5550","url":null,"abstract":"<p><strong>Background and aims: </strong>Insulin resistance is considered the most important key mechanism in the development of nonalcoholic fatty liver disease (NAFLD). Some studies have reported that hyperinsulinemia decreases the hepatic secretion of apolipoprotein (Apo) B. Chronic hyperinsulinemia in NAFLD may be responsible for the accumulation of triglycerides in hepatocytes. We aimed to investigate whether apolipoproteins are related to histological findings in patients with biopsy-proven NAFLD. We also aimed to evaluate the effects of obesity on apolipoproteins and the pathogenesis of NAFLD.</p><p><strong>Methods: </strong>In this cross-sectional study, 91 patients with biopsy-proven NAFLD were included. The control group consisted of 39 healthy subjects who had no history of liver disease or alcohol consumption and were matched for age, gender and smoking. Apoliprotein A1 and Apo B were measured via an immunoturbidimetric method with commercially available OSR6142 Apo A1 and OSR6143 Apo B immunoassay kits on an Olympus AU2700 analyzer.</p><p><strong>Results: </strong>Age, gender, and smoking distribution were similar among nonalcoholic steatohepatitis patients, simple steatosis patients, and controls. The differences in the mean Apo A1 and Apo B levels and the Apo B/A1 ratio among non-alcoholic steatosis, simple steatosis, and control subjects did not reach statistical significance. In addition, patients with obese NAFLD had higher steatosis scores than patients with nonobese NAFLD (p<0.05).</p><p><strong>Conclusions: </strong>Apo A1 and B levels and the B/A1 ratio were not associated with histopathological findings in patients with NAFLD. Fibrosis and ApoB1/A were found to be independent risk factors for metabolic associated fatty liver disease. In addition, obesity increases the grade of hepatic steatosis but does not cause lobular inflammation, ballooning or fibrosis.</p>","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"33 4","pages":"510-516"},"PeriodicalIF":0.0,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142904598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}